Last checked at 9 Jun 2016 07:00
9 June 2016
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Two new accounts added to US platform programme
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added two additional accounts to its platform programme in the USA.
The first account, the sixth platform account in the Company's West Coast territory, is a major hospital in the San Francisco Bay Area. The hospital has placed an initial order for 50 probes and is contracted to buy a minimum of 30 probes per month going forward.
The second account comprises a collection of hospitals in the Company's North-East territory who are working collaboratively to introduce enhanced recovery protocols in bowel surgery with a view to spreading into other types of surgery in due course. The Company is active in two of the participating hospitals, one of which is a large teaching hospital.
These are Deltex's sixth and seventh new platform programme accounts in 2016, bringing the total number of US platform accounts to 24. This further illustrates the success of the Company's ongoing strategy to focus on the USA and develop it as its key market.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"Adoption rates in the USA, our key territory for development, continue to outperform our other areas of focus. Additional platform accounts contribute to recurring sales growth in the USA, where probe revenues in the five months to the end of May are over 50% ahead of the corresponding period in 2015.
"We look forward to adding further accounts to our platform account network and meeting our key milestone of 30 platform accounts in the US in the coming months."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Jonathan Shaw, Group Finance Director Barry Curtis, Company Secretary | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson
|
020 3829 5000
|
Financial Public Relations | |
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.